Objectives. This study investigated the hemostatic status of the right and left atria in patients with mitral stenosis.
(J Am Coll Cardiol 1995;25:107-12)
Systemic thromboembolism is a serious complication in patients with valvular heart disease, and its incidence is highest in those with mitral stenosis (1-7). The incidence of embolism in large groups of such patients is -4%/year (8) . The Framingham Study (9) reported an 18-fold increase in the incidence of stroke in patients who had mitral stenosis and atrial fibrillation compared with matched control subjects. Thus, the prophylactic administration of anticoagulant agents appears to be indicated in selected patients with mitral stenosis, especially those with atrial fibrillation (10) . However, the efficacy of platelet antiaggregant agents, such as aspirin, has not been convincingly established.
Sensitive new biochemical markers for assessing platelet activity and the status of thrombin generation and fibrinolysis have made it possible to evaluate such activities in patients with valvular heart disease, ischemic heart disease, deep vein thrombosis and pulmonary embolism (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . It has been From the Department of Cardiology, Jichi Medical School, Minamikawachi, Tochigi, Japan. This study was supported in part by Grants 5670632 and 5770477 from the Ministry of Education, Culture and Science, Tokyo, Japan.
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reported that plasma levels of D-dimer and thrombinantithrombin III complex (12) and yon Willebrand factor antigen (15) are significantly elevated in patients with mitral stenosis. However, these studies evaluated hemostatic status only at the peripheral level and evaluated blood obtained from the peripheral vein. In the present study, we investigated plasma levels of biochemical markers for platelet activity and the status of thrombin generation and fibrinolysis in the peripheral vein and right and left atria of 12 consecutive patients with rheumatic mitral stenosis who were undergoing percutaneous mitral valvuloplasty. We believe that this is the first report to discuss the hemostatic status of the atria in such patients.
Methods
Clinical characteristics. Between March 1992 and March 1993, 12 patients (2 men, 10 women; mean [_SE] age 53 ± 2 years, range 39 to 68) with severe rheumatic mitral stenosis underwent percutaneous mitral valvuloplasty by the antegrade transseptal approach using an Inoue balloon (21) . Their clinical characteristics are summarized in Table 1 . Eleven patients had chronic atrial fibrillation, and one had sinus rhythm before valvuloplasty. M1 11 patients with atrial fibrillation had re- ceived warfarin therapy for at least 3 months (international normalized ratio 2.0 to 4.0, mean [_+SE] 2.7 _+ 0.1) but no antiplatelet drugs or hemorrheologically active agents, such as analgesic agents and estrogen-containing drugs. According to the practice of our cardiac catheterization laboratory, warfarin administration was stopped on the day of valvuloplasty. Nine patients were in New York Heart Association functional class II and three in class III. One patient had previously undergone commissurotomy, and one had a previous percutaneous mitral valvuloplasty. Criteria for exclusion from valvuloplasty were significant rnitral regurgitation, aortic stenosis, aortic regurgitation, history of systemic embolism, left atrial clot (as detected by two-dimensional transesophageal echocardiography with a biplane probe), diabetes mellitus and renal or hepatic insufficiency. An age-matched control group of 15 normal volunteers (3 men, 12 women; mean age 53 _+ 2 years, range 35 to 66) received no medications. The study was approved by our institututional human investigations committee, and written informed consent was obtained from all patients and volunteers before the study.
All patients underwent M-mode, two-dimensional and Doppler echocardiography on the day before valvuloplasty. Mean (_+SE) left atrial diameter determined by M-mode echocardiography (22) was 59 _+ 2 mm (Table 1) . Yransesophageal echocardiography performed in all patients detected no intracardiac thrombus. Morphologic characteristics of the mitral valve and subvalvular structures were classified using an echocardiographic scoring system (23) .
Cardiac catheterization and valvuloplasty. Right and left heart studies, including measurements of cardiac output, biplane left ventriculography and right atriography, and coronary angiography were performed by the percutaneous technique from the left groin immediately before percutaneous mitral valvuloplasty. This procedure was performed with an Inoue single-balloon catheter (17) . In brief, the balloon catheter was inserted into the left ventricle transseptally according to the Brockenbrough technique. After its distal half was inflated at the left ventricle, the balloon was pulled back to the mitral orifice. It was then fully inflated until its indentation had disappeared. It was then pulled back to the left atrium and deflated. The diameter of the inflated balloon was 24 mm in five patients, 26 mm in six patients and 28 mm in one patient. These manipulations were performed under fluoroscopy with the same predetermined projections as those used in left ventriculography. Effective areas of balloon dilation were determined by geometric analysis and normalized for body surface area, as described previously (24) . The severity of mitral regurgitation was assessed according to the method of Sellers et al. (25) . Pressures in the left atrium and left ventricle were simultaneously recorded to determine the mean transmitral gradient (13.6 _+ 1.6 mm Hg, mean _+ SE) before valvuloplasty (Table 1) . Cardiac output was determined by thermodilution in 11 patients and by the direct Fick method in one with moderate tricuspid regurgitation. Mitral valve area calculated by the Gorlin formula (26) was 0.81 + 0.07 cm 2 (mean _+ SE) before valvuloplasty.
Blood sampling. Samples of the peripheral venous blood were obtained for measurement of molecular markers at 9 AM before percutaneous mitral valvuloplasty to exclude the possible influence of circadian variations (27) (28) (29) . Immediately before the administration of heparin and inflation of balloon during valvuloplasty, blood samples were obtained from the left and right atria through a thermodilution catheter (7F) and an Inoue balloon catheter (12F), respectively. A trained physician carried out blood sampling using the two-syringe technique. A preliminary study showed no difference in the levels of biochemical markers in samples obtained from the same sites through the two types of catheters, and drawing blood samples from these catheters did not cause an artificial increase in the levels of biochemical markers. Nine parts of whole blood were mixed with one part of 3.8% sodium citrate solution for assay of thrombin-antithrombin III complex, plasmin-alphae-plasmin inhibitor complex and von Willebrand factor antigen. Four parts of whole blood were gently mixed with one part of a solution containing sodium citrate, theophylline, adenosine and dipyridamole for assay of platelet factor 4 and beta-thromboglobulin (30) . A volume of 1.6 ml of whole blood was drawn into a plastic tube containing 200 U of heparin and 4,000 klU of aprotinin for assay of fibrinopeptide A and D-dimer. Plasma was separated by centrifugation at 2,000 g for 30 min and stored at -80°C until the molecular markers were assayed.
Plasma assays. Enzyme-linked immunosorbent assay (ELISA) kits (Diagnostica Stago, Asnibres, France) were used for quantitative determination of platelet factor 4 and betathromboglobulin (31 antithrombin III complex, D-dimer and plasmin-alpha 2-plasmin inhibitor complex were also determined with ELISA kits (Diagnostica Stago; Behringe Werke, Marburg, Germany; Agen Biomedical, Brisbane, Australia; and Teijin, Tokyo, Japan, respectively) (32) (33) (34) (35) . Concentrations of von Willebrand factor antigen were determined by ELISA (Diagnostica Stago) (36) , with values expressed as a percent of that obtained in pooled normal plasma. Statistical analysis. Data are expressed as mean value _ SE. Differences were analyzed by one-way analysis of variance combined with the Scheff6 test. Simple linear regression analysis was used to compare measurements obtained by means of catheterization or ultrasound as well as the levels of molecular markers for platelet activity and status of thrombin generation and fibrinolysis; p < 0.05 was considered statistically significant.
Results
Platelet activity. Figure 1 and Table 2 show the plasma levels of platelet factor 4 and beta-thromboglobulin used to reflect platelet activity. Levels of platelet factor 4 in the In patients with mitral stenosis, peripheral blood plasma fibrinopeptide A levels were significantly higher than those in normal subjects, and plasma fibrinopeptide A and thrombin-antithrombin III complex levels in the left atrium were significantly higher than those in the peripheral blood and right atrium. PV = peripheral vein. Data are mean value -+ SE.
peripheral blood did not differ significantly between patients with mitral stenosis and normal subjects. Levels of platelet factor 4 in the patients did not differ significantly with respect to the peripheral blood and right and left atria. Plasma levels of beta-thromboglobulin also did not differ significantly between the patients and normal subjects or the peripheral blood and right and left atria in the patients. Status of thrombin generation. Plasma levels of fibrinopeptide A and thrombin-antithrombin III complex used as a marker of thrombin activity, are shown in Figures 2 and 3 and Table 2 . Peripheral blood levels of fibrinopeptide A in the patients with mitral stenosis significantly exceeded those in the normal subjects. Levels of fibrinopeptide A were significantly higher in the left atrium than in the peripheral blood or right atrium of the patients. Plasma levels of thrombin-antithrombin III complex in the peripheral blood did not differ significantly between patients and normal subjects. However, in the left atrium of the patients, these levels significantly exceeded those in the peripheral blood or the right atrium. There was a significantly positive relation between the plasma levels of fibrinopeptide A and thrombin-antithrombin III complex in the left atrium of the patients (Fig. 4) . Fibrinolytie status. Plasma levels of D-dimer and plasminalpha2-plasmin inhibitor complex, which reflect active fibrinolysis, are shown in Figure 5 and Table 2 . Levels of these molecular markers in the peripheral blood did not differ significantly between patients and normal subjects. Plasma levels of these molecular markers also did not differ significantly in the peripheral blood and right and left atria of the patients.
Levels of von Willebrand factor. Levels of von Willebrand factor antigen in the peripheral blood were significantly higher in the patients than in the normal subjects but did not differ significantly in the peripheral blood and right and left atria of the patients (Fig. 6, Table 2 ).
Relation between biochemical markers and hemodynamic variables. Of the several biochemical markers evaluated in the left atrium of patients with mitral stenosis, fibrinopeptide A and thrombin-antithrombin III complex levels were shown to be significantly increased. We then analyzed the correlation between the levels of these coagulation markers and hemodynamic variables. Plasma levels of fibrinopeptide A and thrombinantithrombin III complex in the left atrium of the patients did not correlate well with the diameter of the left atrium, mean transmitral gradient or reciprocal mitral valve area (Table 3) .
Discussion
Thrombin specifically cleaves fibriuopeptide A from the amino termini of the fibrinogen alpha chain and initiates fibrin generation (37) . Thrombin is very rapidly bound and thereby inactivated by its main physiologic inhibitor, antithrombin III, producing thrombin-antithrombin III complex. Plasma fibrinopeptide A and thrombin-antithrombin III complex levels represent a very sensitive marker for thrombin activity in vivo; direct measurement of free thrombin is impossible because of Figure 6 . Scatterplots showing plasma levels of von Willebrand factor antigen (vWF:Ag) in normal subjects (n = 15) and in the peripheral blood and right (RA) and left (LA) atria of patients with mitral stenosis (MS) (n -12). Peripheral plasma levels of yon Willebrand factor antigen in patients with mitral stenosis significantly exceeded those determined in normal subjects. PV -peripheral vein. Data are mean value _+ SE. its very short half-life. In this study, plasma levels of fibrinopeptide A and thrombin-antithrombin III complex in the left atrium of patients with mitral stenosis significantly exceeded those in the peripheral blood or the right atrium, demonstrating a state of increased coagulability in the left atrium of these patients even during anticoagulation. Hemostatic condition in mitral stenosis. The status of thrombin generation and fibrinolysis in the peripheral blood of patients with mitral stenosis has been studied by several groups (38) . Yasaka et al. (12) reported that levels of fibrinopeptide A, fibrinopeptide B-beta-I 5-42, D-dimer and antithrombin Ill in the peripheral blood were significantly higher in patients with mitral stenosis than in normal subjects. Jafri et al. (13) reported that patients with mitral stenosis who were in sinus rhythm showed a significant increase in D-dimer levels in the peripheral blood over those in control subjects, suggesting that the coagulation system is activated in patients with mitral stenosis. In our study, all but one patient had chronic atrial fibrillation. Thus, chronic atrial fibrillation may partly contribute to the elevated fibrinopeptide A and thrombin-antithrombin III complex levels seen in the left atrium. However, levels of fibrinopeptide A and thrombin-antithrombin III complex levels in the right atrium were not elevated in 11 patients with atrial fibrillation compared with levels in the peripheral blood (Fig. 2) , suggesting that the presence of atrial fibrillation itself does not cause an increase in fibrinopeptide A and thrombin-antithrombin III complex levels in the left as well as the right atrium.
A shortened platelet survival time has been documented in patients with mitral stenosis, suggesting that they have activated platelet activity (39). Fukuda and Nakamura (40) reported that platelet function was increased in all patients with rheumatic valvular disease on the basis of findings of high plasma betathromboglobulin values. In our study, plasma levels of platelet factor 4 and beta-thromboglobulin in the peripheral blood did not differ significantly between patients and normal control subjects. Levels of platelet factor 4 and beta-thromboglobulin tended to increase in each atrium compared with levels in the peripheral blood, but not to a statistically significant extent. We speculate that platelet activity is not increased within the cardiac chambers of patients with mitral stenosis. However, the possibility that platelet function may have been suppressed by warfarin administration cannot be ruled out (41) .
In our study, severity of stenosis on the basis of mitral valve area was not correlated with levels of fibrinopeptide A and thrombin-antithrombin III complex in the left atrium. A spontaneous left atrial echo contrast is often observed in patients with a history of arterial embolization or left atrial thrombi and is associated with conditions that favor stasis of blood in the left atrium in mitral stenosis (42, 43) . Rheologic abnormalities in the left atrium of patients with mitral stenosis may contribute to the hypercoagulable status. However, the incidence of thromboembolism and the size of the mitral orifice do not show a simple correlation (44) . In this study, we observed spontaneous echo contrast in the left atrium of some patients, but there was no relation between its presence and levels of fibrinopeptide A and thrombin-antithrombin III complex in the left atrium (data not shown).
The large multimeric glycoprotein, von Willebrand factor, is found in endothelial cells, plasma and platelet alpha granules and mediates platelet adhesion to the vascular subendothelium. This protein is essential for the formation of platelet thrombi in flow that is characterized by high shear stress (45). Penny et al. (15) reported that the von Willebrand factor antigen concentration in the peripheral blood was significantly higher in patients with mitral stenosis and that this elevation was associated with a significant increase in pulmonary vascular resistance. These investigators speculated that there was increased synthesis of von Willebrand factor in the pulmonary circulation in these patients. In the present study, levels of von Willebrand factor antigen in the peripheral blood of patients with mitral stenosis were significantly higher than those in age-matched normal subjects. However, we observed no correlation between levels of von Willebrand factor antigen and pulmonary vascular resistance (r = 0.09, p = 0.54). Patients with mitral stenosis showed no significant differences in von Willebrand factor antigen levels in peripheral blood and right and left atria. Although elevation of von Willebrand factor may contribute to the thrombotic tendency seen in patients with mitral stenosis, our study could not clarify its site of production. The therapeutic benefit directed at von Willebrand factor in these patients also remains to be clarified.
Adams et al. (46) evaluated 84 patients with mitral stenosis followed up for 20 years and found that patients without anticoagulation had a higher mortality rate than those with anticoagulation. However, there have been no prospective randomized trials to evaluate the efficacy of anticoagulation in the primary prevention of systemic embolism in mitral stenosis. Anticoagulation is generally recommended for treating patients with mitral stenosis, particularly those with atrial fibrillation, a large left atrium or heart failure or patients with a history of systemic embolism (47). Asakura et al. (14) demonstrated that patients with mitral stenosis and atrial fibrillation showed a highly hypercoagulable status. In vivo activation of blood coagulation was more effectively controlled in those patients who received warfarin than in those taking aspirin. However, the incidence of thromboembolism still can not be disregarded with those medications.
Limitation of the study. We cannot rule out completely the effect of puncture of the atrial septum itself on coagulation activity in both atria; needle perforation of the septum and catheter dilation of the septal puncture could cause raw edges of the septal perforation to be exposed to atrial blood. However, the lack of difference in platelet factor 4 and beta-thromboglobulin levels between the left and right atria is somewhat indicative that the septal wound is not a fatal flaw in this study.
Conclusions. We believe that our study demonstrates for the first time that coagulation activity is significantly increased in the left atrium of patients with mitral stenosis even during anticoagulation, which might contribute to the pathogenesis of thromboembolism in mitral stenosis. Our findings also suggest that platelet activity is not significantly increased in the left atrium of these patients.
